Abstract 4691
Background
Acute promyelocytic leukemia (APL) is strongly related to obesity. APL patients have significantly higher body mass index (BMI) than other acute leukemia. In APL patients, BMI over 30 kg/m2 is reported to be a risk factor of all trans retinoic acid (ATRA) induced differentiation syndrome (DS), and associated with inferior disease free survival (DFS) and overall survival (OS). We assessed the impact of obesity associated various factors on APL clinical course.
Methods
We retrospectively reviewed clinical records of the APL patients in our center since January 2008 to May 2019. We used Fisher’s exact test in univariate analysis, logistic regression in multivariate analysis, logrank test in survival analysis.
Results
51 patients were included in this study. The median age was 57 (range: 19-88), 24 females and 27 males. The median BMI was 23.1, 8 (15%) had BMI over 30 kg/m2. All patients were administered ATRA only or ATRA plus anthracycline based chemotherapy. 35 (68%) developed DIC at diagnosis, 18 (35%) developed DS by ATRA administration.47 (92%) achieved complete remission, median suvival was 1304 days (1-6608).9 (17%) experienced relapse.8 (15%) were died by bleeding, another cancer, organ failure. BMI over 30 kg/m2 was associated with high visceral and subcutaneous fat volume(P = 0.01, respectively). High triglyceride (TG) and LDL-cholesterol were independent of high BMI (P = 0.67, =0.54, respectively). In univariate and multivariate analysis, only high TG (over 150 mg/dl) was significantly associated with DIC (odds ratio (OR)= 10.6 (1.6-126.0), p = 0.004, OR = 11.6 (1.9-67.5), p = 0.006, respectively) and DS (OR = 7.31 (1.1-84.2), p = 0.02, OR = 7.7 (1.3-44.0), p = 0.02). BMI, TG, LDL, visceral or subcutaneous fat volume were not significantly affect with OS and DFS. DS onset or high white blood cell count were associated with inferior OS (P = 0.03) or PFS (P = 0.01).
Conclusions
High TG was a major risk factor of DIC and DS in APL treatment. It is possible that TG metabolic pathway will be linked to DIC and DS pathogenesis. Low fat diet or hyperlipidemia treatment may decrease DIC and DS progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract